Wista Laboratories Ltd.

Genting Taurx Diagnostic Centre Sdn Bhd

Björn Olaf Schelter

Claude Michel Wischik

John Mervyn David Storey

Damon Jude Wischik

Helen Christine Shiells

Linda Sommerlade

The invention provides novel regimens for treatment of neurodegenerative disorders utilising methylthioninium (MT)-containing compounds. The regimens are based on novel findings in relation to the dosage of MT compounds, and their interaction with symptomatic treatments based on modulation of a acetylcholinesterase levels.

Administration and dosage of diaminophenothiazines

The invention provides novel dosing regimens for Leuco-Methylthioninium (LMT) compounds which maximise the proportion of subjects in which the MT concentration will exceed concentrations in which therapeutic efficacy in relation to treatment of neurodegenerative disorders such as Alzheimer's disease and rontotemporal dementias can be achieved, while maintaining a desirable clinical profile. Also provided are LMT-containing dosage units and other compositions.

Optimised dosage of diaminophenothiazines in populations

The invention provides novel regimens for treatment of neurodegenerative disorders utilising methylthioninium (MT)-containing compounds. The regimens are based on novel findings in relation to the dosage of MT compounds, and their interaction with symptomatic treatments based on modulation of acetylcholinesterase levels.

This invention relates to methods and systems for determining network connections. It is particularly, but not exclusively, related to methods and systems for determining network connections in sparse networks, and has particular application to EEG data. An aspect of the invention provides a method for identifying, in a network of interacting nodes simultaneously producing signals, connections between said nodes and of estimating connection coefficients between nodes identified as connected which includes the steps of setting to zero connection coefficients where the calculated coherence or partial coherence is below a first predetermined threshold and subsequently setting to zero connection coefficients where the estimated connection coefficients are below a second predetermined threshold, and then re-estimating the connection coefficients for the combinations of nodes for which the connection coefficients have not already been set to zero.

Method and system for determining network connections

The invention describes improved treatments for Frontotemporal dementia based on the use of a methylthioninium compound in combination with a compound which directly modifies synaptic neurotransmission in the brain, such as a symptomatic Alzheimer's disease treatment (e.g. acetylcholinesterase and/or memantine).

Growing community of inventors

Aberdeen, United Kingdom

Björn Olaf Schelter